Testing Saliva Growth Factors
In Support of Stem Cell Therapeutics
Summary For Investors
Background: I retired to Thailand in 2001…and that was the beginning. What began was a whole new career as stem cell scientist and educator, being a founder of the Panama College of Cell Science which offers a 3 year online PhD degree in Stem Cell Medicine. In 2001, Thailand was already treating patients, particularly cardiac patients from the USA, with stem cells harvested from a patient’s blood. This was then sent to Israel for expansion (multiplication), and, upon return, injected into the patients. I had never heard of a stem cell in the United States, let alone any stem cell therapy. But here we were in Bangkok witnessing the parade of Americans coming for stem cell therapy using the patient’s own stem cells. Over the years, the primary therapeutic modality has advanced from the early use of a patient’s own stem cells from peripheral blood, to the current use of stem cells harvested from abdominal tissue via liposuction, and on to the newest procedures involving high dose light activated Platelet Rich Plasma (PRP)- “stem cell therapy without the stem cells”.
What has been missing throughout this development has been objective testing to demonstrate a beneficial effect… or even any effect… in the patient’s condition. Circulating growth factors are known to be involved in stem cell therapeutics. And now, the recent findings that saliva contains nearly identical growth factors as found in the peripheral blood have opened the door to the potential for testing the change in growth factors found in saliva. My company, Bengal Bioscience, intends to lead in saliva testing of growth factors before and after a therapeutic trial, and thereby to support alternative medicine providers and their patients with data demonstrating changes is growth factors before and after a stem cell related therapy.
Walter P Drake CV 2025 Click HERE
Executive Summary
Executive Summary: Bengal Bioscience
Company Name: Bengal Bioscience Inc.
Website: http://www.bengalbioscience.com
Headquarters: Green Cove Springs, Florida, USA
Sector: Stem Cell Therapeutics | Biotechnology | Regenerative Medicine | Biomedical Innovation
Mission Statement
Bengal Bioscience is committed to advancing affordable, accessible, and scientifically validated regenerative therapies, focusing on high-yield, autologous blood-derived therapeutics including platelet-rich plasma (PRP), platelet lysate, and photo-activated biologics. Within this space, the Company has developed a saliva testing protocol for the growth factors and cytokines that mean the most in stem cell therapies. The main focus has been on making the testing affordable because most if not all stem cell therapies are experimental and not covered by medical insurance.
Vision
To become the #1 provider of testing of a wide range of growth factors and cytokine molecules most important to stem cell therapies. Such testing, via easily obtainable saliva samples before and after a treatment, will help to prove the efficacy of such therapies where, as now, no testing occurs or is available due to prohibited cost of equipment and reagents.
Core Offerings & Capabilities
- Saliva based growth factor and cytokine tests before and after therapies, using our home/office kits and marketed primarily to clinicians in the field. Saliva samples, once collected, are dropped into pre-paid mailing envelopes for shipment to our lab for processing. Currently, this is our main focus and there are no other players in this space of offering tests to prove the efficacy of a stem cell therapy.
- Light-Activated Platelet Lysate Therapy
Developer of a cutting-edge therapeutic protocol using high-concentration autologous platelet products activated by controlled light exposure (photoactivation) to optimize the release of growth factors for intravenous administration. Believed by Chief Scientist Walter P. Drake to be the most advanced stem cell therapeutic to date, far superior to Intravenous Stem Cell Therapy. Others have supported the idea of injecting soluble biologicals rather than stem cells, and there are several papers demonstrating curative results.
Applications Include: Chronic illness, autoimmune disease, immune modulation, tissue repair, and anti-aging.• High-Yield Manual PRP Systems
Development of a proprietary manual techniques (non-kit based) for extracting up to 10x higher platelet concentrations using laminar flow hood sterile protocols. Used in some cases in tandem with the addition of “PRP kits”:
Step-by-step visual of the process:
—Blood draw (120 mL)
—Manual PRP/lysate preparation under laminar flow hood
—Light activation (brief photo-exposure)
—Intravenous administration
—All in a clinic or mobile setting, in under 1 hour of processing time.
Advantage: Reduced cost per treatment, superior efficacy potential, and full control over quality assurance.
Market Opportunity
• The global regenerative medicine market is projected to exceed $150 billion by 2030.
• Growing demand for autologous biologic therapies for chronic conditions, cosmetic use, and immune support.
• Bengal Bioscience targets a market gap by delivering affordable, scalable, and clinician-controlled solutions for physicians, other health care providers with prescription authorization, and concierge practices.
Competitive Advantage
• With our primary focus on providing needed testing for stem cell therapeutic procedures where there is none, we expect to stand alone within this space. Our methodology is unique and proprietary, and while we have published our basic procedures, our double immunodiffusion methodology is largely proprietary, making it extremely difficult to be copied.
• Innovative Assay Procedure
• Founder Expertise: Led by Walter P. Drake N.D., Ph.D., Professor of Stem Cell Medicine at Panama College of Cell Science, with 25 years of research experience and acquired knowledge within the stem cell therapy field.
Walter P Drake CV 2025 Click HERE
Funding Requirements
Bengal Bioscience seeks an initial raise of $1.5 million USD to:
1. Purchase of Equipment
2. Equipment Layout and Final Testing of Protocols
3. Saliva Kit Formulation and Packaging
4. Scale Production
5. Complete Clinical Validation
6. Launch Market Entry
Use of Funds (Example Breakdown)
|
Use Case |
% Allocation |
|
Equipment Acquisition and Final Testing Protocols |
20% |
|
Preparation and testing of antiserum reagents to specified molecules known to be important in stem cell therapy |
20% |
|
Legal and Validation of Protocols |
10% |
|
Marketing & Sales Launch |
10% |
|
Operational & Staffing |
15% |
|
Reserve for Contingencies |
25% |
The Opportunity
-
- Transformative testing product with low cost + high impact
- Ready for scale-up and distribution
- Ideal for early-stage investors, medical innovators, or health tech partners
- Help shape and be part of the future of regenerative care—accessible, effective, personalized
Conclusion
With very limited, and in most cases no objective testing to demonstrate the effectiveness of a stem cell treatment modality, Bengal Bioscience stands alone with providing relatively low cost saliva testing to clinicians and health care providers.
Bengal Bioscience is not just a biotech firm—it is a disruptive regenerative medicine platform supporting providers in the delivery of high-impact biologic therapies and now with the addition of objective testing. Practitioners no longer have to rely on the patient’s improved symptoms or testimonials…Bengal Bioscience objective testing will add substantially to the continuing maturation of stem cell medicine.
Now poised for commercialization, Bengal Bioscience is actively seeking visionary partners and investors to fuel its next phase of growth.
